TABLE 2.

Vibrio vulnificus and Vibrio parahaemolyticus antimicrobial profile.

Antibiotic	Conc. μ/ml	Susceptible (%)		Intermediate (%)		Resistance (%)
		Vv	Vp	Vv	Vp	Vv	Vp
Amikacin**	4–64	74	75	5	5	20	20
Amoxicillin/Clavulanic acid	2/1–16/8	89	65	7	18	4	17
Ampicillin	2–16	96	95	3	4	1	1
Ampicillin/Sulbactam	2/1–16/8	100	100	0	0	0	0
Cefepime	0.5–16	67	68	12	8	21	24
Cefotaxime**	0.03–2	66	75	7	4	27	21
Cefoxitin	4–32	30	60	29	9	42	31
Ceftazidime	4–32	57	69	6	2	36	29
Ceftriaxone**	0.5–16	64	65	2	5	35	30
Cephalothin	2–16	38	23	20	16	42	61
Chloramphenicol	2–16	98	98	1	1	1	1
Ciprofloxacin**	0.25–2	98	95	2	5	0	0
Doxycycline**	0.5–8	100	97	0	1	0	1
Imipenem	1–8	84	65	13	17	3	17
Levofloxacin**	0.5–4	100	99	0	0	0	1
Meropenem	0.25–8	74	73	11	9	16	19
Piperacillin	1–64	99	99	1	0	0	1
Piperacillin/Tazobactam	1/4–32/4	100	99	0	0	0	1
Tetracycline**	0.5–8	100	99	0	1	0	1
Trimethoprim/Sulfamethoxazole	2/38–4/76	100	97	0	0	0	3

Vv, Vibrio vulnificus; Vp, Vibrio parahaemolyticus. **CDC recommended antibiotics for Vibrio infection treatment.